• HSD107 Recommendations for the Design and Implementation of a Multidisciplinary Consensus Guidance for Clinical Practice on Advanced Breast Cancer in Portugal

    Dec 1, 2022, 00:00

  • EE17 Economic Evaluation of Patiromer for the Treatment of Hyperkalaemia in CKD Patients With and Without HF in Italy

    Dec 1, 2022, 00:00

  • SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China

    Dec 1, 2022, 00:00

  • EPH114 Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Gree Road to Recovery

    Dec 1, 2022, 00:00

  • EE530 Cost Per Response, Remission and Endoscopic Improvement of Advanced Therapies of Bio-Exposed Patients With Moderately-to-Severely Active Ulcerative Colitis (UC) in France

    Dec 1, 2022, 00:00

  • HTA241 Rare Diseases: The Role of Managed Access

    Dec 1, 2022, 00:00

  • EPH189 Assessing Changes in the Number and Profile of New Cases of Bacterial Sexually Transmitted Infections From 2018-2021: A Descriptive Analysis of German Claims Data

    Dec 1, 2022, 00:00

  • RWD96 The Disparity in the Utilization of Drugs for Multiple Myeloma Using Real-World Data in the US

    Dec 1, 2022, 00:00

  • EE161 Loss of Employment Duration and Productivity for Patients With Different Subtypes and Stages of Lung Cancer

    Dec 1, 2022, 00:00

  • EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

    Dec 1, 2022, 00:00

  • EE250 An Update of Systematic Review of Cost-Utility Studies Conducted From an Indian Perspective

    Dec 1, 2022, 00:00

  • EE470 Zanubrutinib Versus Ibrutinib to Treat Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cost Per Responder Model From a Payer Perspective in the United States

    Dec 1, 2022, 00:00

  • HTA145 Living Network Meta-Analysis for Up-to-Date Comparative Effectiveness: A Case Study in Multiple Myeloma Maintenance

    Dec 1, 2022, 00:00

  • EE681 Costs of Treating Acute Hereditary Angioedema (HAE) Attacks With C1 Inhibitors in Five Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • EPH81 The Productivity Burden of Sleep Apnoea in Australia Over a Lifetime: A Modelling Study

    Dec 1, 2022, 00:00

  • HTA240 Indirect Comparisons of Clinical Effectiveness in NICE HTA Submissions: Software Use Trends, 2000-2022

    Dec 1, 2022, 00:00

  • EE539 Social and Economic Burden of HIV in Russia

    Dec 1, 2022, 00:00

  • CO178 Cardiovascular, Neurological, and Ocular Complications of COVID-19 Among Indian Patients – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis

    Dec 1, 2022, 00:00

  • RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan

    Dec 1, 2022, 00:00

  • HTA224 Commissioning Through Evaluation: RWE for Rituximab in the Management of Idiopathic Membranous Nephropathy

    Dec 1, 2022, 00:00

  • HTA94 Two South African Health Technology Assessment Methods Guides: Which One Is More Suitable for the Assessment and Appraisal of Medicines?

    Dec 1, 2022, 00:00

  • SA2 Use of Systematic Literature Reviews (SLRs) and Meta-Analyses (MA) to Support HTA Submissions: An Application in Pancreatic Cancer

    Dec 1, 2022, 00:00

  • SA54 Physical and Mental Health Among Frontline Healthcare Workers During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • PCR282 Despite the Growing Weight of Patient Voice in Medical Research, Only Few Medical Journals Allow and/or Require Plain Language Summaries (PLS)

    Dec 1, 2022, 00:00

  • HSD49 Improving Influenza Vaccination Rates: Evaluation of Pharmacy Vaccination Model Project During COVID-19 Pandemic in Germany

    Dec 1, 2022, 00:00

  • EE293 Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

    Dec 1, 2022, 00:00

  • MSR22 Strategies for Effective Patient Advocacy Group Engagement in the Development and Fielding of Online Patient Burden Surveys

    Dec 1, 2022, 00:00

  • HTA180 The Value-Generation-Value-Recognition Gap for Novel Gene Therapies in European HTA Systems Using X-Linked Retinitis Pigmentosa as a Case Study

    Dec 1, 2022, 00:00

  • EE660 Cost-Effectiveness of Personalized Nutrition Based on Omic Sciences in Adults With Abdominal Overweight or Obesity: A Within-Trial Analysis and Beyond-Trial Modelling in the United Kingdom and Poland

    Dec 1, 2022, 00:00

  • EE371 Disease Management Costs for Patients With Intermediate-High or High-Risk Renal Cell Carcinoma (RCC) Following Nephrectomy

    Dec 1, 2022, 00:00

  • EE590 Duration and Costs of Hypoparathyroidism After Total Thyroidectomy for Thyroid Cancer: A French Nationwide Claims Database Study (1-YEAR FOLLOW-UP)

    Dec 1, 2022, 00:00

  • Patient Heterogeneity and Equity in Stated Preference Studies

    Dec 1, 2022, 00:00

  • EE456 Cost-Effectiveness of Tenofovir Alafenamide (TAF) for Treatment of Chronic Hepatitis B in Taiwan

    Dec 1, 2022, 00:00

  • MSR102 Variance-Bias Trade-Off in Covariate Adjustment in the Context of Synthetic Control Methods

    Dec 1, 2022, 00:00

  • PCR159 Improving the Physical Function of Wheelchair Fencers

    Dec 1, 2022, 00:00

  • CO98 Influenza Vaccine and Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study in Four Tertiary-Level Hospitals in Peru

    Dec 1, 2022, 00:00

  • PCR149 Quality of Life of Patients With Chronic Wounds

    Dec 1, 2022, 00:00

  • EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study

    Dec 1, 2022, 00:00

  • MT42 Oxidized Zirconium Use in Primary Joint Arthroplasty: A 90-Day Episode of Care Analysis in a Large US Metropolitan Statistical Area (MSA) for Elective Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA)

    Dec 1, 2022, 00:00

  • EPH115 Medical Cost and Prevalence of Diseases Across Different Health Insurance Systems in Japan

    Dec 1, 2022, 00:00

  • PCR218 Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets

    Dec 1, 2022, 00:00

  • HTA236 Early Diagnosis of Breast Cancer Saved Loss of Employment and Productivity for Women: Real World Evidence of Lifetime Impact

    Dec 1, 2022, 00:00

  • RWD131 Investigating Resource Costs and the Experiences of Patients and Healthcare Professionals in the Treatment of Fabry Disease With Enzyme Replacement Therapy – A Multi-Country Study

    Dec 1, 2022, 00:00

  • EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database

    Dec 1, 2022, 00:00

  • EE219 Cost-Effectiveness Analysis of the Use of Indoscyanine Green in Patients Undergoing Laparoscopic Cholecystectomy to Avoid Biliary Tract Injuries From the Perspective of the Colombian Health System

    Dec 1, 2022, 00:00

  • HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review

    Dec 1, 2022, 00:00

  • EE90 Are There Specificities for Assessing Quality of Life and Utilities in Rare Diseases for Economic Evaluation in Fran A Case Study of Published CEESP Opinions

    Dec 1, 2022, 00:00

  • PCR199 Time to First Deterioration in Health-Related Quality of Life (HRQOL) Remains the Most Common Time to Deterioration (TTD) in Non-Small Lung Cancer (NSCLC) Trials

    Dec 1, 2022, 00:00

  • HTA171 Are Global Trials Good Enough to Support the Reimbursement of a New Technology in Asia? A Review of Asian HTA Submissions

    Dec 1, 2022, 00:00

  • EE77 Cost-Effectiveness Analysis of Pharmacogenetic-Guided Treatment in Drug Resistant Depression

    Dec 1, 2022, 00:00

  • HTA198 The Influence of the Claimed Benefit Versus the Given Benefit on the Negotiated Rebate During the German Health Technology Assessment

    Dec 1, 2022, 00:00

  • HSD97 Automated Versus Manual Prior Authorization for Type 2 Diabetes Mellitus Drugs: A Retrospective Study From Israel

    Dec 1, 2022, 00:00

  • HTA248 Could Early Scientific Advice Have Improved Outcomes in Cost-Effectiveness Markets?

    Dec 1, 2022, 00:00

  • RWD92 Persistence and Patterns of Exposure to Omalizumab in Patients With Asthma in France Between 2009 and 2019 (SOLAIR Study)

    Dec 1, 2022, 00:00

  • SA45 Practical Considerations for Developing PICO Statements for Humanistic Burden Reviews: How to Get It Right

    Dec 1, 2022, 00:00

  • EE44 Pain Therapy With Spinal Cord Stimulation (SCS) in Patients With Painful Diabetic Neuropathy (PDN): Results of a Budget Impact Model

    Dec 1, 2022, 00:00

  • EE605 Feasibility Assessment of Using MiToS Staging System for Conducting Health Economic Analysis in Amyotrophic Lateral Sclerosis (ALS)

    Dec 1, 2022, 00:00

  • PCR16 Variables Associated With Carer Quality of Life in England Using a Large, National Data Set

    Dec 1, 2022, 00:00

  • PCR1 Comparison of Infant’s CRY/Fuss Report Between Parental Perception and Recording Analysis, and Its Potential Implications on Parental Mental Health

    Dec 1, 2022, 00:00

  • HPR42 A New Organizational Model to Manage Chronic Diseases With Digital Medicine Tools

    Dec 1, 2022, 00:00

  • EE37 Cost-Utility Analysis of Elecsys Gaad Algorithm Versus Ultrasound Plus -Fetoprotein (AFP) for HCC Surveillance in Patients With Compensated Liver Cirrhosis in the United Kingdom (UK)

    Dec 1, 2022, 00:00

  • EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial

    Dec 1, 2022, 00:00

  • PCR229 Two Simple Methods for Daily Measuring Compliance With Oral Nutritional Supplements in the Community: Electronic Self-Report Method Versus Image-Based Method

    Dec 1, 2022, 00:00

  • HPR57 Do Favourable Access Conditions and Policies for Biosimilars Result in Increased Consumption in the EU4 and the UK?

    Dec 1, 2022, 00:00

  • EE305 Burden of Disease and Cost of Illness of Atopic Dermatitis (AD)

    Dec 1, 2022, 00:00

  • EE554 Costs Comparison Between Dupilumab and Omalizumab in the Treatment of Severe Allergic Asthma in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • CO3 Sensitivity to Change of the Oxford Participation and Activities Questionnaire in People With Parkinson’s

    Dec 1, 2022, 00:00

  • RWD77 Validation of Prevalence and Incidence Rates for Six Different Diseases Using Livingstone: An Online, Automated Analytical Platform

    Dec 1, 2022, 00:00

  • EE202 Estimating the Public Health Benefits of Preventing Herpes Zoster and Postherpetic Neuralgia in Greece by Zoster Vaccines: A Modelling Study

    Dec 1, 2022, 00:00

  • EE204 Cost-Effectiveness of Everolimus Combination Therapy in Patients After Liver Transplantation Focusing on Cancer Risk: A Markov Model Using Real-World Data

    Dec 1, 2022, 00:00

  • EE100 An Approach to Value-Based Pricing for Digital Health Applications in Germany

    Dec 1, 2022, 00:00

  • HSD63 Characteristics and Treatment Patterns of Patients Initiating Cladribine Tablets: A U.S. Commercial and Medicare Advantage Prescription Drug Claims Analysis

    Dec 1, 2022, 00:00

  • HSD92 Operational Savings Generated in an Integrated Care Clinic for Immune-Mediated Skin Disorders

    Dec 1, 2022, 00:00

  • PCR258 Citizens’ Preferences for Robot-Assisted Hip Replacement: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • HTA167 Transition to New Danish HTA Process

    Dec 1, 2022, 00:00

  • EE312 Are Methods Used to Generate Utility Values Adequately Included in Technology Assessments for Children and Adolescents? Lessons From HAS Assessments of Manufacturers’ Cost-Utility Analyses

    Dec 1, 2022, 00:00

  • P42 Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation

    Dec 1, 2022, 00:00

  • EPH141 Dispensing Patterns for Rabies in Humans: A South African Database Analysis

    Dec 1, 2022, 00:00

  • EE563 Evaluating the Cost-Utility of Intravesical Bacillus Calmette-Guérin Versus Radical Cystectomy in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer in the UK

    Dec 1, 2022, 00:00

  • EE73 The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment

    Dec 1, 2022, 00:00

  • EE256 Budget Impact Analysis of the Introduction of a Novel Gene Expression Biomarker Test for Early-Stage Breast Cancer Patients in Cyprus

    Dec 1, 2022, 00:00

  • PCR77 Factors to Consider in Deciding on B/Ts Dmards to Manage Inflammatory Arthritis From a Patient Perspective: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA162 Assessing Literature Reviews in NICE Single and Multiple Technology Appraisals

    Dec 1, 2022, 00:00

  • EPH24 The Impact of COVID-19 Pandemic on Paediatric Vaccination Coverage Rates

    Dec 1, 2022, 00:00

  • MSR109 Can Jointly Modelling PFS and OS With Mixture Cure Models Overcome Data Immaturity Problems?

    Dec 1, 2022, 00:00

  • HPR12 Treatment Inequities Among Cancer Patients Due to Reimbursement: From the Perspective of 130 Medical Oncologists

    Dec 1, 2022, 00:00

  • RWD147 Demonstrating the Application of Real-World Evidence for Health Technology Assessment Using a Federated Data Network

    Dec 1, 2022, 00:00

  • HPR145 Factors of Access to the Market of Innovative Specialties in Algeria: The Case of Hospital Drugs

    Dec 1, 2022, 00:00

  • HSD28 Most Common Treatments in Patients With Treatment Resistant Depression Based on European Cohort Study Real-World Evidence

    Dec 1, 2022, 00:00

  • HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe

    Dec 1, 2022, 00:00

  • SA80 Data Extraction Templates in Systematic Literature Reviews: How Systematic Are We?

    Dec 1, 2022, 00:00

  • RWD133 Assessing the Impact of Bisphosphonates and Selective Estrogen Receptor Modulators in Post-Menopausal Osteoporosis

    Dec 1, 2022, 00:00

  • SA37 Cultural Adaptation and Sociometric Analysis of Aberdeen Varicose Vein Questionnaire

    Dec 1, 2022, 00:00

  • EE98 Healthcare Resource Utilization and Costs Associated With Previously Treated Advanced Non-Small Cell Lung Cancer Patients Without EGFR Mutations or ALK Rearrangements in Korea

    Dec 1, 2022, 00:00

  • EE259 US Reference Pricing Impact on Transparency, Pricing, and Access in the EU4 Final

    Dec 1, 2022, 00:00

  • CO127 Empirical vs Documented Use of Ceftolozane-Tazobactam for the Treatment of Complicated Infections in French Hospital Settings

    Dec 1, 2022, 00:00

  • CO13 Evidence Gap Analysis of the Burden of Illness and Treatment of Primary Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • HTA112 A Pragmatic Payer-Patient Engagement Framework (PPEF) to Support Ethical Formulary Decision Making Process in Rare Disease (RD) Arena in Commercial Payer Settings in the U.S.

    Dec 1, 2022, 00:00

  • HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria

    Dec 1, 2022, 00:00

  • HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

    Dec 1, 2022, 00:00

  • EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil

    Dec 1, 2022, 00:00

  • HSD18 Access to Healthcare Services During COVID-19 Restrictions in Kazakhstan: A Nationwide Survey on COVID-19 and Lifestyle Changes

    Dec 1, 2022, 00:00

  • EE392 Cost-Effectiveness Analysis of Atrial Fibrillation Screening for a 50–65-Year-Old Population With Elevated Stroke Risk

    Dec 1, 2022, 00:00

  • EE432 Budget Impact Analysis of Avelumab + Best Supportive Care (BSC) as First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) in Ireland

    Dec 1, 2022, 00:00

  • CO125 Characteristics of Asthma Patients at GINA's Higher Steps on OCS Treatment: A Cross-Sectional Study in Portuguese Community Pharmacies (EmOCS Study)

    Dec 1, 2022, 00:00

  • PCR182 Validity and Responsiveness of EQ-5D-Y in Children With Haematological Malignancies and Their Caregivers

    Dec 1, 2022, 00:00

  • PCR49 Patient Reported Outcomes in Randomized Controlled Trials of Nervous System and Mental Health Disorders: Current Status in India

    Dec 1, 2022, 00:00

  • EE582 The Principles of the Economic Evaluation and Public Health Committee (CEESP) Doctrine at the French National Authority for Health (HAS)

    Dec 1, 2022, 00:00

  • EE345 Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain

    Dec 1, 2022, 00:00

  • EE199 Impact on Healthcare Resource Utilization and Indirect Costs Among Individuals With Migraine and Preventive Treatment Failure in France, Germany, Italy, Spain and United Kingdom

    Dec 1, 2022, 00:00

  • RWD1 Factors Affecting Korean Medicine Health Care Use of Functional Dyspepsia in Korea: Analysis of Korea Health Panel Survey 2017

    Dec 1, 2022, 00:00

  • HTA65 Socio-Economic Determinants of Health Status During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • HPR51 Identification and Quantification of Implementation Challenges and Costs Associated With Short-Term National-Level Vaccine Switches

    Dec 1, 2022, 00:00

  • EE467 A Review of the Use of Clinical Expert Opinion to Inform Survival Curve Extrapolations in Single Technology Appraisals of New Cancer Drugs by NICE, UK

    Dec 1, 2022, 00:00

  • CO82 The Assessment of Surrogate Endpoints and Their Impact on HTA Recommendations

    Dec 1, 2022, 00:00

  • EE444 Еconomic Evaluation of Medical Activity on Fractional Flow Reserve Measurement (FFR) for Functional Assessment of Epicardial Stenoses in Patients With Stable Coronary Heart Disease

    Dec 1, 2022, 00:00

  • RWD4 Health Care Resource Utilization and Cost (HCRU) Among Treatment-Experienced People Living With HIV (PLWH) Switching to Single Tablet Regimen (STR) or Multi-Tablet Regiment (MTR) Triple Therapy Since 2018

    Dec 1, 2022, 00:00

  • PCR234 Patient Preference in Cervical Cancer Screening

    Dec 1, 2022, 00:00

  • EE366 Healthcare Resource Consumption and Related Costs in Patients Under Antiretroviral Therapies: Findings From Real-World Data in Italy

    Dec 1, 2022, 00:00

  • HTA261 Comparison of Molecular Tests for Detection of NTRK Gene Fusions in Patients With Advanced Solid Tumours- A Systematic Review and Economic Evaluation

    Dec 1, 2022, 00:00

  • HTA214 Distributional Cost-Effectiveness Analysis of Lung Cancer Treatments From an NHS England Perspective

    Dec 1, 2022, 00:00

  • EE654 Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece

    Dec 1, 2022, 00:00

  • EE114 Cost-Utility Analysis of Lung Cancer Screening Combined With Cardiovascular Disease and Chronic Obstructive Pulmonary Disease Screening

    Dec 1, 2022, 00:00

  • CO36 Safety and Efficacy of Augmentation Therapy in Patients with Alpha-1-Antitrypsin Deficiency: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE84 Cost of Follow-Up After an Ischemic Heart Disease Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • EE180 Budget Impact Model of Feiba in the Management of Hemophilia Patients With Inhibitors in the Egyptian Public Healthcare System

    Dec 1, 2022, 00:00

  • EE532 Health Impact Projection of Anti-PD-(L)1 Inhibitors in 13 Cancers Indications in France

    Dec 1, 2022, 00:00

  • EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

    Dec 1, 2022, 00:00

  • PCR277 Nutritional Status Assessment in Patients With Lung Cancer

    Dec 1, 2022, 00:00

  • EE639 Health Care Resource Utilization and Costs Among Persons With a Permanent or Temporary Stoma: A Swedish Register Study

    Dec 1, 2022, 00:00

  • EE522 Budget Impact Model of Anti-Obesity Drugs and Bariatric Surgery in People With Obesity in South Korea

    Dec 1, 2022, 00:00

  • HPR180 Eligibility of Orphan Drugs for Preferential Reimbursement in Egypt

    Dec 1, 2022, 00:00

  • CO32 A Systematic Review of Efficacy and Safety of Mitapivat to Treat Hemolytic Anemia in Pyruvate Kinase Deficiency

    Dec 1, 2022, 00:00

  • RWD160 Racial Disparity in the Treatment of Psoriasis in the US

    Dec 1, 2022, 00:00

  • MT22 Qualitative Content Analysis of Secondary Digital Health Terms – Are They Sufficient for Health Outcomes Research Purposes?

    Dec 1, 2022, 00:00

  • RWD16 Role of Real-World Evidence for Treatments Granted Access Under Cancer Drugs Fund: Lessons and Insights From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • EE514 Treatment-Related and Non-Treatment-Related Out-of-Pocket Costs by Amyotrophic Lateral Sclerosis Disease Stage: A Cross-Sectional Patient Survey and Retrospective Chart Review

    Dec 1, 2022, 00:00

  • PCR244 Burden of Myelodysplastic Syndromes Part I: Systematic Literature Review of Epidemiologic and Humanistic Burden

    Dec 1, 2022, 00:00

  • EE147 Estimating the Causal Effect of Early Use of Erythropoietic Stimulating Agents in Intermediate-1 to Low-Risk MDS Patients: An Application of the Longitudinal Targeted Maximum Likelihood Estimation

    Dec 1, 2022, 00:00

  • PCR66 How Would the Choice of the Multi-Attribute Utility Instrument Affect the Cost-Effectiveness of Cancer Interventions? A Comparison of the FACT-8D and the AQoL

    Dec 1, 2022, 00:00

  • PCR73 Health-Related Quality of Life Outcomes and Associated Factors for Young Adults with Experience of Severe Malaria in Uganda: A Cross-Sectional Comparison with Community Controls

    Dec 1, 2022, 00:00

  • CO19 Adjunctive Albumin Infusion During Large-Volume Paracentesis May Improve Days to Next Hospital Readmission in Cirrhotic Patients

    Dec 1, 2022, 00:00

  • EE274 Orphan Drug Pricing Comparisons in Low-, Middle- and High-Income Countries

    Dec 1, 2022, 00:00

  • MSR57 Study of Time-Course Relationship Using Model-Based Network Meta-Analysis: A Linear Time-Course Model

    Dec 1, 2022, 00:00

  • P40 An Investigation Into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

    Dec 1, 2022, 00:00

  • CO65 Clinical and Economic Burden Among Patients With Prurigo Nodularis Compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study

    Dec 1, 2022, 00:00

  • EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finland

    Dec 1, 2022, 00:00

  • HPR185 The International Impact of National Institute for Health and Care Excellence (NICE) Decisions

    Dec 1, 2022, 00:00

  • EPH39 Association Between Patient-Physician Communication and Perceived Mental Health Status Among United States Adults With Cancer

    Dec 1, 2022, 00:00

  • HTA89 Androgen Receptor Inhibitors for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2022, 00:00

  • EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression

    Dec 1, 2022, 00:00

  • CO75 Advanced Multi-Layer, Watertight Closure in Total Joint Replacement: A Retrospective Study

    Dec 1, 2022, 00:00

  • HTA231 Estimation of Expected Years of Living With Disability in Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE629 Methodological Concerns in the Medico-Economic Modeling of Adjuvant Management

    Dec 1, 2022, 00:00

  • PCR85 Modifying QALY

    Dec 1, 2022, 00:00

  • EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

    Dec 1, 2022, 00:00

  • P52 Patient Preferences for Diagnostic Imaging Services Among Underserved and Rural Populations: Blueprint for Value-Based Incentives Incorporating Individual Preference Heterogeneity

    Dec 1, 2022, 00:00

  • EPH159 Creating an Online Patient Education Program for Female Population Who Are Over 50 Years Old

    Dec 1, 2022, 00:00

  • PCR289 Building a Practical Strategy and Framework for Diverse and Inclusive Involvement of Patients and Carers in Real World Data Evidence Generation (RWDEG)

    Dec 1, 2022, 00:00

  • EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants

    Dec 1, 2022, 00:00

  • HTA268 Impact of Independence and Transparency on Drug Availability and Time to Market: EU4 Qualitative and Quantitative Analysis of Pricing, Reimbursement, and Access Processes

    Dec 1, 2022, 00:00

  • PCR70 Avalglucosidase Alfa (AVA) Improves Symptoms and Functioning in Late-Onset Pompe Disease (LOPD) Patients vs Alglucosidase Alfa (ALG): Post-Hoc Analyses of Patient-Reported Outcomes (PROs) From COMET Trial

    Dec 1, 2022, 00:00

  • EPH179 The Economic Impact of Diabetic Ketoacidosis (DKA) in People with T1DM at High Risk for DKA: A Structured Literature Review

    Dec 1, 2022, 00:00

  • HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?

    Dec 1, 2022, 00:00

  • HTA29 Digital Health Interventions: A Review of Economic Evaluation Guidelines From Health Technology Assessment Agencies

    Dec 1, 2022, 00:00

  • EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • EE132 Budget Impact Related to Complications on Pre-Bariatric Surgery Patients in Brazilian Public Healthcare System

    Dec 1, 2022, 00:00

  • P14 The Impact of Long-Term Follow-Up on Mean Survival Estimates From Immuno-Oncology Clinical Trials

    Dec 1, 2022, 00:00

  • EE659 A Novel Modelling Method for Estimating Cost Impact of a Non-Prescriptive Digital Intervention in Type 2 Diabetes

    Dec 1, 2022, 00:00

  • EE107 Ponesimod Indicated for Patients With Active Relapsing Forms of Multiple Sclerosis: A Budget Impact Analysis From the Italian National and Regional Health Care Service Perspective

    Dec 1, 2022, 00:00

  • P36 Can Real-World Evidence (RWE) Drive European, UK, and US Payer Decisions in the Reassessment of Oncology Therapies?

    Dec 1, 2022, 00:00

  • EE396 Public Health Impact and Cost-Effectiveness of Herpes Zoster Vaccination for Older Adults in the Netherlands

    Dec 1, 2022, 00:00

  • RWD121 Assessing the Use of Variational Bayes for Large Real-World Data

    Dec 1, 2022, 00:00

  • EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients

    Dec 1, 2022, 00:00

  • EE270 Economic Burden of Young Onset Parkinson's Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE642 Economic Impact Before and After Expensive Drug Reimbursement With Diabetic Macular Edema in South Korea

    Dec 1, 2022, 00:00

  • EPH118 Healthcare Systems Sustainability and Resilien Creating an Index

    Dec 1, 2022, 00:00

  • EE557 Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome With Constipation in China

    Dec 1, 2022, 00:00

  • HTA41 Modelling Long-Term Treatment Effects for Chronic Progressive Conditions

    Dec 1, 2022, 00:00

  • RWD115 Modelling the Effect of Multi-Indication Treatment in Patients With Multimorbidity Using Population-Scale Linked Electronic Health Records for Healthcare Policy and Decision-Making

    Dec 1, 2022, 00:00

  • PCR20 Diversity of Patient Support Programs for Severe Asthma Treated with Biologic Therapies – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • PCR22 Measurement Properties of 15-Item Singapore Caregiver Quality of Life Scale (SCQOLS-15) in Family Caregivers of Patients With Heart Diseases

    Dec 1, 2022, 00:00

  • PCR76 Do We Really Need a Study Looking at That? A Best-Worst Scaling Study Assessing Methodological Research Priorities According to the Patient Preference Research Community

    Dec 1, 2022, 00:00

  • EPH195 Psychometric Evaluation of the Hungarian Version of Oxford Capabilities - Mental Health Questionnaire

    Dec 1, 2022, 00:00

  • HPR47 Comparison of the Characteristics and Costs of Vulnerable Populations Hospital Stays in France Regarding Their Coverage Type Between 2011 and 2021

    Dec 1, 2022, 00:00

  • PCR87 Influence of Nutritional State and the Phase Angle in the Health Related Quality of Life and Clinical Outcome in Head and Neck Cancer

    Dec 1, 2022, 00:00

  • EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis

    Dec 1, 2022, 00:00

  • EPH178 Impact Assessment of the COVID-19 Pandemic on Varicella Incidence Across Europe Using Digital Epidemiology Methods

    Dec 1, 2022, 00:00

  • HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?

    Dec 1, 2022, 00:00

  • EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma

    Dec 1, 2022, 00:00

  • RWD84 The Role of Real-World Evidence in Cell and Gene Therapy Regulatory and Health Technology Assessment Decisions

    Dec 1, 2022, 00:00

  • MSR123 Use of Real-World Data in Cost-Effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EPH18 Neovascular Age-Related Macular Degeneration: Prevalence and Treatment With Anti-VEGF From the Perspective of the Italian National Health System

    Dec 1, 2022, 00:00

  • PCR198 Contemporary Trends in the Use of Generic Patient-Reported Outcome Measures in Pediatric Clinical Trials: An Analysis of Clinicaltrials.Gov

    Dec 1, 2022, 00:00

  • EE624 Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the Vaccination Programme in the UK

    Dec 1, 2022, 00:00

  • EE1 Healthcare Resource Utilization and Cost of Treatment-Resistant Depression: A Six-Year Trend and Comparative Analysis in Hong Kong

    Dec 1, 2022, 00:00

  • HPR91 Disease-Specific Hardship Financing in India: A Pooled Cross-Section Analysis of Inpatient and Outpatient Cases

    Dec 1, 2022, 00:00

  • RWD79 Burden of Hospitalization, Costs and Comorbidities in Medicaid Patients With Veno-Occlusive Disease (VOD): Analysis of National In-Patient Hospital Database

    Dec 1, 2022, 00:00

  • HPR156 Payment and Reimbursement Models for Innovative High-Priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences

    Dec 1, 2022, 00:00

  • HTA48 An Integrated Approach to HTA Assessments in the EU: Hype or Hope?

    Dec 1, 2022, 00:00

  • HSD32 Early Access in Fran Reasons for Refusals and Impact on Market Access

    Dec 1, 2022, 00:00

  • PCR253 Establishing Content Validity of Three New Patient Reported Outcome (PRO) Measures for Use in HIV Long-Acting Oral Antiretroviral Therapy (LA-OART) Clinical Trials

    Dec 1, 2022, 00:00

  • EPH184 A Systematic Review of the Burden of Critical Limb Ischemia (CLI) Among Patients With Peripheral Arterial Disease in Japan

    Dec 1, 2022, 00:00

  • Applications of Machine Learning and Artificial Intelligence in Real-World Studies

    Dec 1, 2022, 00:00

  • EE59 Assessing Economic Cost of Treatment of an Episode of Malaria and Its Effect on the Well-Being of Households in Comé District Health (CDH), South-West Benin

    Dec 1, 2022, 00:00

  • EE41 Healthcare Resource Utilization of Severe, Uncontrolled T2LOW and Non-T2LOW Asthma in Finland During 2018-2021

    Dec 1, 2022, 00:00

  • EE127 Evidence and Uncertainty in an Iterative Decision-Making Framework

    Dec 1, 2022, 00:00

  • HTA107 Direct Market Access for Medecines: Analysis of Eligible Products in France and Comparison With Current German System

    Dec 1, 2022, 00:00

  • HPR54 Patient Impact of Transferring Hospital-Only Medicines Dispensing to Community Pharmacies: A Longitudinal Prospective Study

    Dec 1, 2022, 00:00

  • EE386 Impact of Publication of the French Commission for Economic and Public Health Evaluation (CEESP) Doctrine on the Conclusions of Its Economic Opinions

    Dec 1, 2022, 00:00

  • PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer

    Dec 1, 2022, 00:00

  • CO6 Influence of Serum Phosphate on the Predictive Utility of Serum Alkaline Phosphatase for Renal Outcomes in Chronic Kidney Disease Patients – A Prospective Cohort

    Dec 1, 2022, 00:00

  • EE450 The Burden of Intraoperative Hypotension in Patients Undergoing High-Risk Noncardiac Surgery and the Role of a Machine Learning-Derived Algorithm to Optimize Its Management: What Are We Missing Ignoring Supportive Innovations?

    Dec 1, 2022, 00:00

  • EPH14 Prevalence of Depression in Japan and the US Populations Before and During the COVID-19 Pandemic: A Retrospective Observational Study Using Real-World Data

    Dec 1, 2022, 00:00

  • EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience

    Dec 1, 2022, 00:00

  • PCR129 Demonstrating the Value of RWE Gained From Online Health Platforms: Understanding and Reducing Burden in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • MSR52 Target Trial Emulation (TTE) for Real World Data Analyses to Support HTA Decisions

    Dec 1, 2022, 00:00

  • MSR74 Can Artificial Intelligence (AI) Replace a Human Reviewer in Systematic Literature Review (SLR)? Validation of the LIVESTARTTM Tool

    Dec 1, 2022, 00:00

  • MSR43 The Use of Safety-Engineered Devices in Preventing Needle-Stick Injuries: A Budget Impact Analysis

    Dec 1, 2022, 00:00

  • EE603 Economic Evaluation of C5 Inhibitors in Patients With Paroxysmal Nocturnal Haemoglobinuria – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EPH122 Healthcare Consumptions in Patient with Early Ageing Disease: Case-Control Study From a National Claims Database

    Dec 1, 2022, 00:00

  • EPH60 Social and Geographical Inequalities in the Choice of Foot Therapy as Preventive Care of Diabetic Foot Ulcers: A Nationwide Registry Study on Danish Diabetes Patients

    Dec 1, 2022, 00:00

  • RWD29 Use of Telemedicine Services and Health Outcomes in Hypertensive Patients in Pre- and Post-COVID-19 Periods in the United States

    Dec 1, 2022, 00:00

  • RWD163 Age-Related Cataract: Patient Characteristics and Real-World Treatment Patterns in the United States

    Dec 1, 2022, 00:00

  • EE108 Economic Evaluation of the IGRA Screening Test for the Detection of Micobacterium Tuberculosis Infection: An Analysis for the Italian Health System

    Dec 1, 2022, 00:00

  • EPH165 Inequalities in Health Care Attention of Severely Malnourished Children in Remote and Conflicts Zones

    Dec 1, 2022, 00:00

  • HTA35 Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM)

    Dec 1, 2022, 00:00

  • MSR3 A Novel Approach for Minimizing Immortal Time Bias in Observational Studies

    Dec 1, 2022, 00:00

  • MT14 How Should Clinical Outcomes Factor Into Purchasing Decisions About Macintosh-Style Laryngoscopes?

    Dec 1, 2022, 00:00

  • PCR92 Treatment Preference of Moderate or Severe Hemophilia a Patients in Taiwan

    Dec 1, 2022, 00:00

  • HPR142 The Impact of Cost-Shifting Policies on the Pharmaceutical Sector in Greece During the Financial Crisis

    Dec 1, 2022, 00:00

  • MSR65 Survival Estimates Using Hazard Ratios Derived From Network Meta-Analyses: Is More Guidance Needed?

    Dec 1, 2022, 00:00

  • HPR83 Unequal Access of Innovative Dermatology Products Across Canada

    Dec 1, 2022, 00:00

  • CO61 Clinical Profile and Healthcare Resource Use of ANCA-Associated Vasculitis: A Real-World Analysis in Italy

    Dec 1, 2022, 00:00

  • PCR114 Patient-Voice RWE: Comparative Burden Collected From an Online Social Platform

    Dec 1, 2022, 00:00

  • EE494 A Cost-Benefit Evaluation for Trivalent to Quadrivalent Influenza Vaccination Switch for 40+ Years Old Dyslipidemia Patients With and Without Previous Cardiovascular Event in Colombia

    Dec 1, 2022, 00:00

  • EPH209 Metformin 15-Year Consumption Analysis in Selected European Countries

    Dec 1, 2022, 00:00

  • HTA95 Analysis of Neurological Conditions Submissions to the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) From 2001 to 2021

    Dec 1, 2022, 00:00

  • EPH153 Increased Prevalence of Post-Traumatic Stress Syndrome Among Healthcare Workers During the Coronavirus Epidemic

    Dec 1, 2022, 00:00

  • PCR111 Assessing Anxiety and Depression Among Gravidas

    Dec 1, 2022, 00:00

  • PCR228 Developing Treatment Attributes for a Patient Preference Survey in Inflammatory Bowel Disease

    Dec 1, 2022, 00:00

  • SA16 Enhancing Clinical Trial Diversity and Representation Through Data-Adaptive Targeted Learning: A Tale of Lurking Berkson Bias

    Dec 1, 2022, 00:00

  • EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

    Dec 1, 2022, 00:00

  • EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France

    Dec 1, 2022, 00:00

  • EE600 Cumulative Cardiovascular or Renal Disease (CVRD) Hospital Costs for Type 2 Diabetics Free of CVRD at Baseline: A 5-Year Cohort Study in the SNDS Nationwide Claims Database

    Dec 1, 2022, 00:00

  • EE579 Economic and Humanistic Evidence in Early-Stage Hepatocellular Carcinoma (HCC) Post Liver Resection or Ablation – A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • EE575 Cost-Effectiveness of Low-Dose Computed Tomography Screening for Lung Cancer

    Dec 1, 2022, 00:00

  • CO31 Associations Between CDR-Global and Meaningful Outcomes in Patients With Alzheimer's Disease

    Dec 1, 2022, 00:00

  • HTA192 Precision Versus Non-Precision Oncology Drug Submissions to the National Centre for Pharmacoeconomics in Ireland

    Dec 1, 2022, 00:00

  • HPR148 The Impact of Patient Access Schemes on the Access of Innovative Oncology Medicines in Asia-Pacific Region: A Targeted Review

    Dec 1, 2022, 00:00

  • SA13 The Impact of the COVID-19 Pandemic on Collaboration and Innovation in Antiviral Drug Development: A Multi-Stakeholder Systems Dynamics Analysis

    Dec 1, 2022, 00:00

  • MSR78 Population Attributable Fraction Based on Sufficient Causal Framework for Mediation Settings - Evaluation of Resource Distribution on Prevention and Treatment for Stroke

    Dec 1, 2022, 00:00

  • EPH63 Exploring the Potential Public Health Benefits of a Respiratory Syncytial Virus (RSV) Vaccine Candidate (Ad26.RSV.preF/RSV) Among Individuals Aged 65 Years and Older in the UK: A Preliminary Mathematical Modelling Approach

    Dec 1, 2022, 00:00

  • PCR68 Systematic Literature Review of Health State Utility Values in Patients With Huntington's Disease: Evidence From the Europe and United States

    Dec 1, 2022, 00:00

  • HTA50 The Architecture of Clinical Prediction Model Research: A Phased Approach

    Dec 1, 2022, 00:00

  • MSR27 Lessons Learned From Successful Real-World Evidence (RWE) Studies Supporting Drug Effectiveness in Regulatory Approvals

    Dec 1, 2022, 00:00

  • EE166 Cost-Effectiveness of the Pneumococcal Conjugate Vaccine 10 Versus 13 on Pneumococcal Disease in Children in Sweden

    Dec 1, 2022, 00:00

  • HPR4 ISPOR HEOR Trends Over Time: What Is the Influence of Macro HTA Changes?

    Dec 1, 2022, 00:00

  • HPR23 A Comparative Analysis of Biosimilar Competition in European Markets of TNF-Alpha Inhibitors

    Dec 1, 2022, 00:00

  • EPH51 The Health and Economic Burden of Bushfires in Australia Between 2021 and 2030: A Modelling Study

    Dec 1, 2022, 00:00

  • MT13 A Dynamic Budget Impact Analysis of Surgical Treatment for Obesity in Greece

    Dec 1, 2022, 00:00

  • HTA56 Is Evidence on Environmental Impact Included in Health Technology Assessment and Does It Influence Decision-Making?

    Dec 1, 2022, 00:00

  • SA77 Considerations for Patient Identification and Enrolment for Retrospective Studies for the Collection of Long-Term Follow-up Data

    Dec 1, 2022, 00:00

  • EE635 Direct Comparison of Prophylaxis Cost in Patients With Severe Hemophilia A With and Without Inhibitors With Hemostatic Agents Versus the Use of Emicizumab in Guatemala

    Dec 1, 2022, 00:00

  • HTA243 Health Technology Assessment and Reimbursement of Medical Devices in England, France, and Germany

    Dec 1, 2022, 00:00

  • CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • HTA83 Role of Quality of Life in Health Technology Assessment Agency Final Recommendations: Insights and Lessons From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • CO58 Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib With Capmatinib in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC) With MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • EPH53 The Role of Incentives- Parents’ Intention to Vaccinate Their 5- to 11-Year-Old Children with the COVID-19 Vaccine in Israel

    Dec 1, 2022, 00:00

  • EE24 Health Economic Evaluation of Replacing PCV13 With PCV15 in the Danish Childhood Vaccination Programme

    Dec 1, 2022, 00:00

  • HTA223 The Current Status and Challenges of Value Assessment in Prevention and Treatment for Alzheimer’s Disease Dementia in Japan

    Dec 1, 2022, 00:00

  • CO147 Comparative Efficacy and Safety of Pharmacological Interventions for Managing Sickle Cell Disease Complications in Children and Adolescents: A Systematic Review With Network Meta-Analyses

    Dec 1, 2022, 00:00

  • HSD67 Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management Between Pharmacies and Primary Care in Portugal: A Multicenter Quasi-Experimental Pragmatic Controlled Trial (USFarmácia®)

    Dec 1, 2022, 00:00

  • SA42 The Proliferation of Living Systematic Reviews (LSRS) - Dead on Arrival? A Review of LSR Methodology

    Dec 1, 2022, 00:00

  • PCR179 Estimating Health Utilities in Patients with Epilepsy Using the SF-6D

    Dec 1, 2022, 00:00

  • HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study

    Dec 1, 2022, 00:00

  • PCR99 Exploring Relative Weighting and Ranking of Potential Bolt-on Item for the Eq-5D-5L-Hk by Pairwise Comparison in Hong Kong Context

    Dec 1, 2022, 00:00

  • PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies

    Dec 1, 2022, 00:00

  • SA24 Effects of Navigated rTMS for the Hemiparetic Upper Extremity Motor Function in Stroke Patients – Pilot Study

    Dec 1, 2022, 00:00

  • SA18 Development and Application of a Taxonomy on the Beneficial Effects of Oral Anticoagulant Switching in Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EE631 Cost Minimization Analysis of the Switch to a New Immunization Schedule With a Hexavalent (DTAP-HBV-HIB-IPV) Vaccine in Algeria

    Dec 1, 2022, 00:00

  • HPR146 What Are the Opportunities for Flat Pricing of Innovative Medicines Across the EU4 and UK?

    Dec 1, 2022, 00:00

  • EE232 Evaluate Healthcare Resource Utilization (HCRU) Among Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Active Disease

    Dec 1, 2022, 00:00

  • EPH154 The Connection Between the Lunar Cycles and the Number of Births in Hungary

    Dec 1, 2022, 00:00

  • HPR103 Pricing Negotiations of ASMR IV Drugs in Fran Impact of the Latest LEEM-CEPS Framework Agreement

    Dec 1, 2022, 00:00

  • EPH203 Estimating the Impact of COVID-19 Pandemic on Gynaecology Treatment in England

    Dec 1, 2022, 00:00

  • EE515 Cost Per Responder Analysis of Methotrexate Versus Other Therapies in the Treatment of Moderate to Severe Plaque Psoriasis in Italy

    Dec 1, 2022, 00:00

  • HTA125 The Relationship Between Value and Price in the Free-Pricing Period and Post-Assessment Price in Germany: A Case Study in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • HSD23 Operational Waste Savings on Health in a Value-Based Patient Drug Safety Program

    Dec 1, 2022, 00:00

  • EE354 Budget Impact Analysis of Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2022, 00:00

  • HPR174 Social Value Evaluation of Long-Term Care Insurance in Korea: Social Return on Investment Approach (SROI)

    Dec 1, 2022, 00:00

  • EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • HTA110 The Value of Real-World Evidence (RWE) in Melanoma in Health Technology Assessment (HTA) Appraisals

    Dec 1, 2022, 00:00

  • CO141 Using LiveSLR Platform to Evaluate the Impact of Duration of Treatment (DOT) on Progression Free Survival (PFS) in Multiple Myeloma (MM)

    Dec 1, 2022, 00:00

  • EE561 Estimation of the Economic Burden of Renal Complications of Diabetes in Algeria

    Dec 1, 2022, 00:00

  • MSR90 Moving Beyond QALYs: A Composite Indicator to Measure the Benefit of Hearing Implants

    Dec 1, 2022, 00:00

  • EPH156 Treatment Patterns and Characteristics of People With Newly Diagnosed Major Depressive Disorder Across the Komodo Claims Database 2018-2020

    Dec 1, 2022, 00:00

  • EE182 Budget Impact Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • EE344 A Systematic Review: Model-Based Cost-Effectiveness Analyses (CEAs) of Guideline-Directed Disease-Modifying Medical Therapies (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF)

    Dec 1, 2022, 00:00

  • HSD55 Expanding Vaccine Competencies to Community Pharmacists: Modelling Organizational and Economic Impacts of New Human Papilloma Virus (HPV) Vaccines Pathways in France

    Dec 1, 2022, 00:00

  • CO62 Prophylaxis Treatment for Patients With Hemophilia A Without Inhibitors: Experience Monitoring Survey on the Use of Damoctocog Alfa Pegol

    Dec 1, 2022, 00:00

  • HPR62 Equity and Outcome Events in Patients With Hidradenitis Suppurativa: Exploring Effect Modifiers Associated With HS Diagnostic Delay

    Dec 1, 2022, 00:00

  • RWD9 Real-World Relative Dose Intensity in Patients With Advanced or Metastatic Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors in Sweden

    Dec 1, 2022, 00:00

  • HPR65 Prevalence as a Driver of Treatment Cost for Drugs in the Rare Disease Field in Italy

    Dec 1, 2022, 00:00

  • CO42 Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anaemia of Chronic Kidney Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2022, 00:00

  • EPH40 Polyconsultant Patient: A Dynamic Definition for Users Attending Primary Care Emergency Services

    Dec 1, 2022, 00:00

  • EPH55 The Prevalence of Obesity and Its Implications in China: A Narrative Review of Literature

    Dec 1, 2022, 00:00

  • MSR81 Alternative Approaches to the Analysis of Utility Data: Atopic Dermatitis

    Dec 1, 2022, 00:00

  • HTA239 The Challenge of Confidential Commercial Arrangements in Health Technology Assessment: How Often Do They Feature in NICE Technology Appraisal Evaluations?

    Dec 1, 2022, 00:00

  • P28 Evidence-Informed Deliberative Process for Health Technology Assessment in Spain

    Dec 1, 2022, 00:00

  • EE377 Healthcare Utilization and Costs Among Acutely Hospitalized Older Adults

    Dec 1, 2022, 00:00

  • EE201 Survival Analysis Methods Used in Immuno-Oncology NICE Appraisals

    Dec 1, 2022, 00:00

  • PCR189 Health-Related Quality of Life in Patients Receiving Oral Anti-Coagulants: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

    Dec 1, 2022, 00:00

  • EE72 Magnetic Resonance Imaging-Based Prostate Cancer Screening: Differences in the Cost-Effectiveness Using Evidence From Diagnostic Cohorts Versus Screening-by-Invitation Trial

    Dec 1, 2022, 00:00

  • HSD105 Cost Savings Benefits of Operational Waste Minimization in a Care Program by Cohorts of Babies on Treatment With Palivizumab

    Dec 1, 2022, 00:00

  • SA41 Kinesiophobia After Returning to Play in Football

    Dec 1, 2022, 00:00

  • EE676 Impact of Using Innovative Antineoplastic Drugs on Cancer Mortality in Russia

    Dec 1, 2022, 00:00

  • RWD140 Benefits and Challenges of Deterministic, Probabilistic, and Patient-Mediated Approaches to Linking Patients’ Clinical Trial Data (CTD) and Their Real-World Data (RWD)

    Dec 1, 2022, 00:00

  • SA72 Comparing EQ-5D-5L, Propr, Sf-6D and TTO Utilities in Patients With Chronic Skin Diseases

    Dec 1, 2022, 00:00

  • HSD86 Contribution of Clinical Pharmacy Services to the Achievement of Diabetes and Hypertension-Related Quality Measures Among Medicare Patients

    Dec 1, 2022, 00:00

  • MSR80 Impact of Donor Ferritin Testing on Iron Deficiency Prevention and Blood Availability in Fran A Cohort Simulation Study

    Dec 1, 2022, 00:00

  • EPH56 Trends in Human Papillomavirus (HPV) Vaccine Coverage Rates (VCR) in Fran A Claims Data Study

    Dec 1, 2022, 00:00

  • RWD53 Recurrence of Major Adverse Cardiovascular Events (MACE) in Patients Who Had a Prior Myocardial Infarction (MI): An Analysis Based on German Claims Data

    Dec 1, 2022, 00:00

  • HSD35 Healthcare Resource Utilization (HCRU) in Treatment of Patients With Localized/Locally Advanced Prostate Cancer (LPC/LAPC) in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2022, 00:00

  • PCR161 Being Active Is Not Enough – Combination of Physical Activity, Sedentary Behaviour and Sleep Characteristic Shows More Positive Effect on Infertility Related Quality of Life in Women Undergoing Art

    Dec 1, 2022, 00:00

  • P8 Role Preferences in Medical Decision Making: Implications for Health Preference Research

    Dec 1, 2022, 00:00

  • HSD41 Development of 'Quality of Care for Patients With Advanced Illnesses (QCPAI)' Instrument for Measuring the Quality of End-of-Life Care From Patients’ Perspective

    Dec 1, 2022, 00:00

  • HSD66 The Association Between Patients’ Socio-Demographic Characteristics and Biologic Treatment Initiation: Real-World Evidence From a 14-Year Cohort of Ulcerative Colitis Patients in Israel

    Dec 1, 2022, 00:00

  • EE610 Economic Investment for Saving a Year of Life Following the Israeli Government's Actions in the First Year of the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HSD109 Predictors of Saudi Arabian Pharmacists’ Intent to Provide Medication Counselling

    Dec 1, 2022, 00:00

  • EE362 Evaluating the Cost-Effectiveness of Refluxstop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)

    Dec 1, 2022, 00:00

  • EE412 HBA1C Point-of-Care Testing for Diabetes Control in Low-Income Remote Areas: A Cost-Parity Analysis

    Dec 1, 2022, 00:00

  • MSR115 Comparison of Statistical Models to Address Ceiling Effect in Utility Scores: A Simulation Study

    Dec 1, 2022, 00:00

  • MT4 Study Design Recommendations in ISO Standards for High-Risk Medical Devices: A Systematic Review of the HORIZON2020 Core-MD Project

    Dec 1, 2022, 00:00

  • SA7 Reduced Health Care Resource Utilisation and Costs Following a Switch From Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in COPD Patients in a Real-World Primary Care Setting in England

    Dec 1, 2022, 00:00

  • MSR121 Clinical Meaning of the Family-Reported Outcome Measure (FROM-16): A Novel Dimension of Real-World Data

    Dec 1, 2022, 00:00

  • CO101 Burden of Post-Stroke Spasticity: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • EE425 Economic Modeling of Web Embolization vs Coiling vs Stent-Assisted Coiling for the Endovascular Treatment of Unruptured Intracranial Aneurysms

    Dec 1, 2022, 00:00

  • CO33 A Systematic Literature Review (SLR) of Comparative Efficacy Measures in Randomized Controlled Trials (RCTS) of Adjuvant Treatment in Localized Renal Cell Carcinoma (RCC)

    Dec 1, 2022, 00:00

  • EPH188 The Burden of Cancer Among Enrollees Insured Through Commercial Plans in the US (2019-2020)

    Dec 1, 2022, 00:00

  • EE497 Healthcare Resource Utilization and Costs by Cardiovascular Risk Level: Results From the Latino Study

    Dec 1, 2022, 00:00

  • CO41 Systematic Literature Review of the Survival, Humanistic and Economic Impact of Systemic Corticosteroid Use

    Dec 1, 2022, 00:00

  • EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy

    Dec 1, 2022, 00:00

  • P22 Value of Information - Consolidated Health Economic Evaluation Reporting Standards: A Checklist Extension

    Dec 1, 2022, 00:00

  • MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods

    Dec 1, 2022, 00:00

  • EE303 Distribution and Predictors of Haemophilia-Related Direct Medical Cost in the United Kingdom: Analysis of Data From the CHESS I and CHESS II Burden of Illness Studies

    Dec 1, 2022, 00:00

  • EE21 Costs of Hemophilia in Ukraine

    Dec 1, 2022, 00:00

  • EE307 Costs of Treating Soft Tissue Sarcomas and Infantile Fibrosarcoma in Pediatric Patients in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • EE339 Budget Impact Analysis of Insulin Glargine-300U/Ml (GLA-300) for Treatment of T1DM and T2DM in Algerian Setting

    Dec 1, 2022, 00:00

  • HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations

    Dec 1, 2022, 00:00

  • SA55 Literature Review and Meta Analysis of Alternative Autologous Vein in Below Knee Lower Limb Surgical Bypass in Patients With Critical Limb Ischemia Pad

    Dec 1, 2022, 00:00

  • EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France

    Dec 1, 2022, 00:00

  • EE205 Cost-Effectiveness of Adherence Intervention for Tuberculosis Treatments in South Korea Using Discrete Event Simulation Model

    Dec 1, 2022, 00:00

  • EE217 Population Genomic Screening for Tier 1 Genomic Applications: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • EPH71 Factors Associating With the Severity of Soccer Injury Among Men and Women Professional Teams

    Dec 1, 2022, 00:00

  • CO43 The Role of Different Biomarkers in the Prognosis of COVID-19 Infection

    Dec 1, 2022, 00:00

  • PCR18 An Exploratory Retrospective Social Listening Study to Identify Patient Experiences Associated With Cutaneous Lupus Erythematosus (CLE)

    Dec 1, 2022, 00:00

  • PCR255 The EQ Health and Wellbeing (EQ-HWB) and the Eq Health and Wellbeing Short (EQ-HWB-S) as an Outcome Measure in Mental Health and Well-Being: A Comparison to the EQ-5D-5L, EQ-5D-3L and the Short Warwick-Edinburgh Mental Well-Being Sca ...

    Dec 1, 2022, 00:00

  • EE534 Economic Evaluations of HIV-1 Disease in South Africa – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • HSD82 Real-World Assessment of Antiplatelet Treatment Therapies for Patients With Acute Coronary Syndrome (ACS) in the United Kingdom

    Dec 1, 2022, 00:00

  • An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure

    Dec 1, 2022, 00:00

  • EPH111 Causes of Medication Administration Errors in a University Hospital in Brazil

    Dec 1, 2022, 00:00

  • HPR184 Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access

    Dec 1, 2022, 00:00

  • HTA249 Method in the Madness – Acceptance of Indirect Evidence in Joint Clinical Assessments

    Dec 1, 2022, 00:00

  • CO120 Evidence Gap Analysis of the Burden of Illness and Treatment of Pemphigus Vulgaris and Foliaceus

    Dec 1, 2022, 00:00

  • SA1 The Use of Multi-Criteria Decision Analysis (MCDA) to Support Decision-Making in Healthcare: An Updated Systematic Literature Review

    Dec 1, 2022, 00:00

  • EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)

    Dec 1, 2022, 00:00

  • EPH117 Coinfections in COVID-19 Patients in India: A Systematic Review

    Dec 1, 2022, 00:00

  • EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC)

    Dec 1, 2022, 00:00

  • SA79 Association Between Antibiotic Exposure and Survival Among Patients Diagnosed With Advanced Melanoma or Advanced Non-Small Cell Lung Cancer (NSCLC) Treated With Immune Checkpoint Inhibitor (ICI) Therapy

    Dec 1, 2022, 00:00

  • PCR291 Preferences for Key Features of Gonadotropin-Releasing Hormone Analogues Among Women With Endometriosis in the United States

    Dec 1, 2022, 00:00

  • HPR39 Access to Orphan Drugs in Hungary

    Dec 1, 2022, 00:00

  • HTA66 Price Increases of Prescription Drugs in Sweden – In Which Cases Are They Approved?

    Dec 1, 2022, 00:00

  • HTA250 Health Technology Assessment Policy and Guideline Changes in the EU-5 During the COVID-19 Pandemic Era: An Insight Into Trends and Drivers

    Dec 1, 2022, 00:00

  • Award Winners

    Dec 1, 2022, 00:00

  • CO104 Real-World Impact of a Prescription Digital Therapeutic on Retention in Treatment and Relapse Indicators in Patients With Opioid Use Disorder

    Dec 1, 2022, 00:00

  • MSR47 A Stepwise Approach for Assessing the Feasibility of Population-Adjusted Indirect Treatment Comparisons

    Dec 1, 2022, 00:00

  • HPR152 Impact of Brexit-Induced Changes to Regulatory Approval on UK Access to Medicines

    Dec 1, 2022, 00:00

  • EE268 Per-Member Per-Month (PMPM) Expenditure Value in Oncology: Updating a Focused Literature Review

    Dec 1, 2022, 00:00

  • EE22 Average CET Limit: Is It Possible to Introduce a Single CET for the Whole EEA?

    Dec 1, 2022, 00:00

  • CO153 Mind-Body Modalities for Healthcare Workers in the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • PCR109 Optimism, Social Support and Psychosocial Impact Among Breast Cancer Survivors: The Mediating Effect of Resilience

    Dec 1, 2022, 00:00

  • RWD98 Variation in COVID-19 Length of Stay Due to Social Factors in the US – Estimation Using Integration of CDC/ATSDR's Social Vulnerability Index (SVI) and Healthcare Claims Data

    Dec 1, 2022, 00:00

  • EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis

    Dec 1, 2022, 00:00

  • A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies

    Dec 1, 2022, 00:00

  • HPR36 Evaluating Patient Preference Information in Regulatory Decision-Making

    Dec 1, 2022, 00:00

  • MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop

    Dec 1, 2022, 00:00

  • EE491 Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US

    Dec 1, 2022, 00:00

  • EE598 Heterogeneity in Cost-Effectiveness of SGLT2IS Versus DPP4IS According to Baseline Characteristics: A Model-Based Analysis

    Dec 1, 2022, 00:00

  • EE158 Economic Burden of Cervical Cancer in Bulgaria

    Dec 1, 2022, 00:00

  • MSR59 Replication and Extrapolation From RCTs to Observational Data to Predict Treatment Effects: Why, What, How

    Dec 1, 2022, 00:00

  • EE83 Cost-Effectiveness Analysis of an Active Transcutaneous Bone Conduction Implant for Patients With Conductive or Mixed Hearing Loss or Single-Sided Deafness in Turkey

    Dec 1, 2022, 00:00

  • PCR171 Considerations for Successful Implementation of Patient-Reported Outcomes in Real-World Evidence Generation: Interviews With Patients and Stakeholders

    Dec 1, 2022, 00:00

  • CO49 3D Visualisation Systems: Advantages for Cataract Surgery

    Dec 1, 2022, 00:00

  • CO86 Clinical Outcomes of Diabetic Macular Edema Patients Treated With Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab Phase 3 Clinical Trials

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36 (current)
  • 37
  • 38
  • 39
  • 40
  • »